Guy Spier spent decades hunting for undervalued securities. Turns out the real mispriced asset was his remaining lifespan. Glioblastoma has a median survival rate of fifteen months, which is coincidentally longer than most retail traders stay solvent after discovering options.
The article wants you to believe this is inspirational. Man gets cancer. Man rethinks priorities. Man pivots from compounding capital to funding rare disease research. Beautiful redemption arc. One problem: Spier made his fortune following Warren Buffett's playbook of buying businesses with sustainable competitive advantages and holding forever. Cancer has an unbeatable moat. It literally kills the competition by killing you.
Value investing requires patience. Decades of patience. Buy when everyone panics. Hold through cycles. Let intrinsic value reveal itself. Glioblastoma operates on a different timeline. The disease moves fast. Spier suddenly discovered that his entire investing philosophy—built on delayed gratification and long-term thinking—becomes spectacularly useless when your long term is measured in months. Not exactly the Warren Buffett annual letter vibes he was going for.
He's funding rare disease research now. Noble. Admirable. Also the investing equivalent of panic-selling at the bottom, except instead of dumping your portfolio, you're dumping your entire worldview because the market—your body—just sent you a terminal delisting notice. All those years studying balance sheets and calculating price-to-book ratios, and the one asset he needed to analyze was his own mortality. Probably should have diversified into healthcare screening earlier. Classic concentration risk.
The Warren Buffett disciples love talking about circle of competence. Stay within what you understand. Spier understood financials, competitive moats, margin of safety. He did not understand oncology. Few do. Glioblastoma has a five-year survival rate under ten percent, which is still better odds than timing the market based on a value investor's cancer diagnosis changing his philanthropic priorities.
Retail traders will read this and feel inspired to reassess their own lives. They will not. They'll go right back to losing money on SPY puts while Spier funds actual scientists doing actual work. At least his capital allocation finally makes sense.
Photo by Paul White on Unsplash
Leave a Comment